Opioid Related Disorders

The FDA has issued a complete response letter to Orexo for OX124, a high-dose naloxone nasal spray for opioid overdose reversal.

To expertly utilize polypharmacy, it is imperative that clinicians stay abreast of new literature, check for drug-drug interactions, and be aware of emerging trends in drug use.

Review tapering challenges and strategies for benzodiazepines in this Special Report article.

Petros Levounis, MD, MA, talks addiction, buprenorphine, his year as president of the APA, and more at the 2024 Annual Meeting.

This first update in 20 years is contained in a recent rule issued by SAMHSA.

What is new in research on opioid use disorder?

How can telehealth aid in the treatment of opioid use disorders in this patient population?

What is new in research on SUDs?

An expert addresses some common concerns about the drug and some effective ways clinicians can initiate the treatment at the 2023 Annual Psychiatric Times™ World CME Conference.

Today is International Overdose Awareness Day!

The funds will be distributed over the course of 5 years to support preclinical through phase 2 studies.

From informed consent in treatment with psychedelics to an anti-fentanyl antibody that may reverse the signs of carfentanil overdose, here are highlights from the week in Psychiatric Times.

The series explores the origins of the first opioid crisis in the United States.

“We expect this antibody to be a valuable new weapon for fighting the opioid crisis.”

From an examination of the fentanyl epidemic to the connection between ADHD medication and height, here are highlights from the week in Psychiatric Times.

The AMA, substance abuse experts share their thoughts on this decision and what it means for psychiatric clinicians and their patients.

From the impact of patients’ overdose deaths on physicians to addressing America’s mental health crisis, here are highlights from the week in Psychiatric Times.

A patient loss does not undo or discard the multitude of meaningful life changing and life preserving work done.

The FDA has accepted the NDA for nasal nalmefene, OPNT003, to treat opioid overdose.

What are the most pertinent drug trends to be aware of in 2023?

We may be one step closer to nonprescription naloxone.

From traumatic brain injury to the dangers of excessive social media usage, here are highlights from the week in Psychiatric Times.

Opioid use, addiction, and overdose in youth continue to increase. What can be done?

The NCCHC and 166 national organizations recently signed a letter to Senate leadership advocating for increased access to buprenorphine.